Latest News - Bausch+Lomb

Monday, October 16, 2017 | Product Releases, Bausch+Lomb

Bausch + Lomb Introduces Envista MX60E IOL

Bausch + Lomb announced the introduction of the enVista MX60E with StableFlex technology, the company's next-generation hydrophobic acrylic lens. The enVista MX60E features AccuSet haptics, whi…

Read the full story

Wednesday, October 04, 2017 | Product Releases, Bausch+Lomb

Bausch + Lomb Introduces Biotrue ONEday for Astigmatism Contact Lenses in Europe

Bausch + Lomb announced the introduction of Biotrue ONEday for Astigmatism daily disposable contact lenses in 20 countries in Europe. This latest contact lens advancement provides the convenience of a…

Read the full story

Wednesday, September 06, 2017 | Product Releases, Bausch+Lomb

Bausch + Lomb Introduces Ocuvite Eye Vitamin Adult 50+ Formula Minigels

Bausch + Lomb announced the launch of Ocuvite Adult 50+ Formula Minigel daily eye vitamins that help replenish vital nutrients that eyes can lose as they age, according to a company news release. The …

Read the full story

Wednesday, August 16, 2017 | Miscellaneous, Bausch+Lomb, Valeant

FDA: Inspection Issues at Bausch + Lomb Manufacturing Plant in Tampa Facility are Being Resolved

Valeant announced that the FDA confirmed it intends to issue a Voluntary Action Indicated (VAI) inspection classification for its Bausch + Lomb manufacturing facility in Tampa. With this confirmation,…

Read the full story

Wednesday, August 09, 2017 | FDA Approval/Clearance, Bausch+Lomb

Bausch + Lomb Receives FDA 510(k) Clearance for the Therapeutic Use of Boston XO and Boston XO2 Materials

Bausch + Lomb announced it has received 510(k) clearance from the FDA for the therapeutic use of its Boston XO and Boston XO2 materials in treating several ocular surface diseases. The Boston XO and B…

Read the full story

Monday, August 07, 2017 | Product Releases, Bausch+Lomb

Bausch + Lomb Launches Stellaris Elite for Retina Surgery

Bausch + Lomb announced the US launch of the Stellaris Elite vision enhancement system for retina surgery. This new system features multiple advancements as well as the ability to seamlessly integrate…

Read the full story

Wednesday, July 12, 2017 | Product Releases, Bausch+Lomb

Bausch + Lomb Launches Fortifeye Capsular Tension Ring

Bausch + Lomb announced the US launch of the FortifEYE capsular tension ring (CTR), a preloaded, sterile, nonoptical implant indicated for the stabilization of the crystalline lens capsule in the pres…

Read the full story

Wednesday, June 21, 2017 | Product Releases, Retina, Bausch+Lomb

Bausch + Lomb Unveils AMD Virtual Experience with State-of-the-Art Technology at Optometry’s Meeting

Bausch + Lomb announced the launch of a new virtual reality tool using state-of-the-art technology. The Age-Related Macular Degeneration (AMD) Virtual Experience, unveiled during the annual meeting of…

Read the full story

Tuesday, June 06, 2017 | Acquisitions/Mergers, Bausch+Lomb, Carl Zeiss Meditec, Valeant

Report: Valeant in Talks to Sell Bausch + Lomb's Surgical Business to Carl Zeiss

Valeant is in in talks to sell its Bausch & Lomb unit’s surgical products business to Carl Zeiss Meditec, according to a Bloomberg report, which cited people familiar with the matter. Valean…

Read the full story

Monday, May 22, 2017 | Product Releases, Bausch+Lomb

Bausch + Lomb Introduces Renu Advanced Formula Multi-Purpose Solution

Bausch + Lomb announced the launch of "renu Advanced Formula" multi-purpose solution for soft and silicone hydrogel contact lenses. The formula combines three disinfectants and two surfactan…

Read the full story

Wednesday, May 10, 2017 | Medical Studies, Bausch+Lomb

Bausch + Lomb Reports Updated Results of the ARMOR Study

Bausch + Lomb announced updated results from the ARMOR (Antibiotic Resistance Monitoring in Ocular MicRoorganisms) surveillance study, the only multicenter, nationwide survey of antibiotic resistance …

Read the full story

Tuesday, May 09, 2017 | Clinical Trials, Bausch+Lomb, Valeant

Bausch + Lomb Announces PDUFA Date For Luminesse

Bausch + Lomb announced that the FDA accepted the new drug application (NDA) for brimonidine tartrate ophthalmic solution, 0.025% (Luminesse), and set a PDUFA action date of December 27, 2017. Lumines…

Read the full story

Wednesday, May 03, 2017 | Conferences, ASCRS, Bausch+Lomb

Bausch + Lomb Invites Surgeons to Test Drive New Next-Generation Phacoemulsification Platform at the ASCRS Meeting in Los Angeles

Bausch + Lomb announced that surgeons can sign up to test drive the new Stellaris Elite vision enhancement system, the company’s next generation phacoemulsification platform, at a wet lab in its…

Read the full story

Tuesday, May 02, 2017 | Conferences, Bausch+Lomb

Bausch + Lomb Letter to Eye Care Professionals: Taking Phaco into the Future

Chuck Hess, Vice President & General Manager, U.S. Surgical, Bausch + Lomb, wrote the following letter to eye care professionals detailing new products and plans for the upcoming ASCRS meeting in …

Read the full story

Wednesday, April 26, 2017 | FDA Approval/Clearance, Bausch+Lomb

Bausch + Lomb Receives 510(k) Clearance from FDA for Vitesse Vitrectomy System

Bausch + Lomb announced that it has received 510(k) clearance from the FDA for Vitesse, the first and only hypersonic, 100% open port vitrectomy system, according to a company news release. This new t…

Read the full story
Load More